Accès gratuit
Numéro
Med Sci (Paris)
Volume 22, Numéro 8-9, Août–Septembre 2006
Page(s) 755 - 760
Section M/S revues
DOI https://doi.org/10.1051/medsci/20062289755
Publié en ligne 15 août 2006
  1. Boshoff C, Weiss R. AIDS-related malignancies. Nat Rev Cancer 2002; 2 : 373–82.
  2. Gatti RA, Good RA. Occurrence of malignancy in immunodeficiency diseases. A literature review. Cancer 1971; 28 : 89–98.
  3. Penn I, Starzl TE. Malignant lymphomas in transplantation patients : a review of the world experience. Int Z Klin Pharmakol Ther Toxikol 1970; 3 : 49–54.
  4. Lejeune FJ. High dose recombinant tumour necrosis factor (rTNF alpha) administered by isolation perfusion for advanced tumours of the limbs : a model for biochemotherapy of cancer. Eur J Cancer1995; 31A : 1009–16.
  5. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy : moving beyond current vaccines. Nat Med 2004; 10 : 909–15.
  6. Pardoll D. Does the immune system see tumors as foreign or self ? Annu Rev Immunol 2003; 21 : 807–39.
  7. Van der Bruggen P, Traversari C, Chomez P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991; 254 : 1643–7.
  8. Boon T, Coulie PG, Van den Eynde B. Tumor antigens recognized by T cells. Immunol Today 1997; 18 : 267–8.
  9. Echchakir H, Mami-Chouaib F, Vergnon I, et al. A point mutation in the alpha-actinin-4 gene generates an antigenic peptide recognized by autologous cytolytic T lymphocytes on a human lung carcinoma. Cancer Res 2001; 61 : 4078–83.
  10. Heath WR, Carbone FR. Cross-presentation, dendritic cells, tolerance and immunity. Annu Rev Immunol 2001; 19 : 47–64.
  11. Spiotto MT, Yu P, Rowley DA, et al. Increasing tumor antigen expression overcomes « ignorance » to solid tumors via crosspresentation by bone marrow-derived stromal cells. Immunity 2002; 17 : 737–47.
  12. Huang AY, Golumbek P, Ahmadzadeh M, et al. Bone marrow-derived cells present MHC class I-restricted tumour antigens in priming of antitumour immune responses. Ciba Found Symp 1994; 187 : 229–44.
  13. Huang AY, Bruce AT, Pardoll DM, et al. In vivo cross-priming of MHC class I-restricted antigens requires the TAP transporter. Immunity 1996; 4 : 349–55.
  14. Gong J, Apostolopoulos V, Chen D, et al. Selection and characterization of MUC1-specific CD8+ T cells from MUC1 transgenic mice immunized with dendritic-carcinoma fusion cells. Immunology 2000; 101 : 316–24.
  15. Restifo NP, Ying H, Hwang L, et al. The promise of nucleic acid vaccines. Gene Ther 2000;7 : 89–92.
  16. Marshall JL, Hoyer RJ, Toomey MA, et al. Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses. J Clin Oncol 2000; 18 : 3964–73.
  17. Rosenberg SA, Zhai Y, Yang JC, et al. Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. J Natl Cancer Inst 1998; 90 : 1894–900.
  18. Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002; 298 : 850–4.
  19. Russell JH, White CL, Loh DY, et al. Receptor-stimulated death pathway is opened by antigen in mature T cells. Proc Natl Acad Sci USA 1991; 88 : 2151–5.
  20. Rosenberg SA. Shedding light on immunotherapy for cancer. N Engl J Med 2004; 350 : 1461–3.
  21. Pages F, Berger A, Camus M, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 2005; 353 : 2654–66.
  22. Abouzahr S, Bismuth G, Gaudin, C, et al. Identification of target actin content and polymerization status as a mechanism of tumor resistance after cytolytic T lymphocyte pressure. Proc Natl Acad Sci USA 2006; 103 : 1428–33.
  23. Chouaib S. Integrating the quality of the cytotoxic response and tumor susceptibility into the design of protective vaccines in tumor immunotherapy. J Clin Invest 2003; 111 : 595–7.
  24. Dong J, Grunstein J, Tejada M, et al. VEGF-null cells require PDGFR alpha signaling-mediated stromal fibroblast recruitment for tumorigenesis. EMBO J 2004; 23 : 2800–10.
  25. Polverini PJ, Leibovich SJ. Induction of neovascularization in vivo and endothelial proliferation in vitro by tumor-associated macrophages. Lab Invest 1984; 51 : 635–42.
  26. Silzle T, Randolph GJ, Kreutz M, et al. The fibroblast : sentinel cell and local immune modulator in tumor tissue. Int J Cancer 2004; 108 : 173–80.
  27. Perdrizet GA, Kaneko H, Buckley TM, et al. Heat shock protects pig kidneys against warm ischemic injury. Transplant Proc 1990; 22 : 460–1.

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.